Wilson Therapeutics appoints Erik Penser as liquidity provider
Wilson Therapeutics AB (publ) has appointed Erik Penser Bankaktiebolag as liquidity provider for the company’s share which is listed in the Mid Cap segment on Nasdaq Stockholm.
This undertaking means in brief that the liquidity provider will set continuous bid and offer prices for Wilson Therapeutics’ shares with a maximum spread, i.e. the difference between the bid and offer price, while liquidity will be provided in the share through a guaranteed minimum volume of shares on the bid and offer side.
The purpose is to reduce the difference between bid and offer price and increase the liquidity of the share.
The measures under the undertaking will commence on June 16, 2016.
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Wilson Therapeutics AB (publ)
Org nr 556893-0357
Västra Trädgårdsgatan 15
SE-111 53 Stockholm
The information in the press release is such that Wilson Therapeutics is required to disclose publicly in accordance with the Swedish Securities Market Act. The information was submitted for publication on June 16, 2016 at 8:00 a.m.